Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole

Area of Science:

• Cardiology
• Pharmacology
• Gastroenterology

Background:

• Antiplatelet agents for coronary heart disease (CHD) can cause gastrointestinal (GI) side effects.
• Omeprazole is known to prevent and treat these GI side effects.
• Combining clopidogrel with aspirin increases the risk of GI ulcers and bleeding.

Purpose of the Study:

• To investigate the impact of omeprazole on the antiplatelet efficacy of clopidogrel.
• To determine if omeprazole interferes with clopidogrel's ability to inhibit platelet aggregation.

Main Methods:

• Coronary heart disease patients on clopidogrel and aspirin received omeprazole (20 mg daily for 10 days).
• Platelet aggregation was measured using the VerifyNow P2Y12 assay, assessing platelet reactivity units (PRU).
• Platelet reactivity was categorized as low (LPR <85 PRU), normal (NPR 85-208 PRU), or high (HPR >208 PRU).

Main Results:

• Mean PRU values showed a non-significant change from 154 ± 85.89 before omeprazole to 169.4 ± 56.15 after.
• Most patients maintained PRU values below the high on-treatment platelet reactivity (HPR) cutoff (>208 PRU).
• A small number of patients shifted between NPR and HPR categories, but the overall trend did not indicate a significant reduction in clopidogrel's antiplatelet effect.

Conclusions:

• Omeprazole administration did not significantly reduce the antiplatelet effect of clopidogrel in CHD patients.
• The study did not support the hypothesis that omeprazole increases the risk of high platelet reactivity when used with clopidogrel.
• Further research may be warranted to fully elucidate the interaction between proton pump inhibitors and antiplatelet agents.